Ortoma AB (ORT-B) Fair Value & Analysis
Healthcare · SE · Market cap 400M SEK (≈ $41.8M) · ISIN SE0005676103
What is Ortoma AB really worth?
Below-average quality, and trading another 459% above our fair value of kr 1.31.
As of Aug 13, 2026, the fair value of Ortoma AB is kr 1.31 per share against a price of kr 7.32, so the fair value sits 82% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
Fair value as of: Aug 13, 2026
From 7 valuation models · updated 23 days ago
Share price +1.5% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 1.57). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range kr 6.50 – kr 36.40 · fair‑value band kr 1.06 – kr 1.57 · the kr 7.32 price screens above the kr 1.31 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Ortoma AB (ORT-B) currently trades at kr 7.32, while our model-based Fair Value estimate is kr 1.31, implying the stock looks roughly 458.7% overvalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bull case: the Asset-Based group reads highest at a median of kr 2.12 per share, and 0 of the 7 models we run sit above the kr 7.32 price. Bear case: the Multiples group reads lowest at kr 1.31, and 7 of the 7 models stay below the price. Evidence for this calculation is low.
Trailing-twelve-month revenue stands at 42.9M SEK. Revenue declined 60.2% year over year. It earns a return on equity of −26.5%. Fundamentals as of Aug 13, 2026
Our scenario range runs from kr 1.06 (bear case) to kr 1.57 (bull case); at kr 7.32, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 78% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −82%, ORT-B screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 7 models by family
Widest divergence: Asset-Based (kr 2.12) versus Multiples (kr 1.31). Highest evidence: FCF DCF (74).
Notify me when ORT-B reaches fair value
Put ORT-B on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 21
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Ortoma AB (publ) provides orthopedic surgical products in Sweden. It offers Ortoma Treatment Solution (OTS), an orthopedic digital, server-based integrated AI platform designed to optimize patient outcomes through surgical planning, precision surgical navigation, post-operative verification, and follow-up; OTS Plan, a software that processes and assists …
Full company description
Ortoma AB (publ) provides orthopedic surgical products in Sweden. It offers Ortoma Treatment Solution (OTS), an orthopedic digital, server-based integrated AI platform designed to optimize patient outcomes through surgical planning, precision surgical navigation, post-operative verification, and follow-up; OTS Plan, a software that processes and assists surgeons during pre-operative planning and post-operative follow-up; and OTS Guide, an intra-operative navigation tool guiding surgeons to place the implant in the pre-operatively planned position. The company was incorporated in 2001 and is based in Gothenburg, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ortoma AB reported revenue of 64.6M SEK in FY2025 versus 0 SEK in FY2021. Reported net income was −19.2M SEK in FY2025.
ORT-B screens 459% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | −34% |
| Edwards Lifesciences Corporation EW | $89.78 | $41.02 | −54% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | −2% |
Compare Ortoma AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Ortoma AB (ORT-B) overvalued or undervalued?
What is the fair value of ORT-B?
What is the quality score of ORT-B?
What is the revenue of Ortoma AB (ORT-B)?
What is the net profit margin of ORT-B?
Watch Ortoma AB in the live analysis
One click puts Ortoma AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.